Literature DB >> 27990684

Transjugular closure of secundum atrial septal defects.

Hao-Ju Dong1, Tai-Bing Fan1, Bin Li1, Wei-Jie Liang1, Shu-Bo Song1, Yu Han1, Kai-Yuan Wu1, Si-Jie Zhou1.   

Abstract

OBJECTIVE: This study reports the results of a steerable delivery system under the guidance of transesophageal echocardiography (TEE) for the treatment of transjugular closure of secundum atrial septal defects (ASD).
METHODS: From July 2015 to May 2016, 33 patients underwent transjugular closure of a secundum ASD under general anesthesia with TEE guidance. The right internal jugular vein was punctured and a FuStar™ steerable sheath was implanted into the right atrium and aligned vertically with the septum, and a closure device was deployed to close the defect.
RESULTS: Thirty-two patients with an ASD were successfully occluded; one patient required ASD closure on cardiopulmonary bypass. Procedure time ranged from 5 to 15 (8.2 ± 3.8) min. The length of stay was three to five days after the operation. The follow-up time ranged from 1.1 to 11.0 (5.5 ± 1.5) months. There was no valve regurgitation, no malignant arrhythmias, no device dislocation, or other serious complications.
CONCLUSIONS: A steerable delivery system under the guidance of TEE is a safe, effective, and cosmetic method for the transjugular closure of secundum ASDs.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27990684     DOI: 10.1111/jocs.12930

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  2 in total

Review 1.  Atrial septal defect closure: indications and contra-indications.

Authors:  Alain Fraisse; Monica Latchman; Shiv-Raj Sharma; Selin Bayburt; Pascal Amedro; Giovanni di Salvo; Alban Elouen Baruteau
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Transjugular closure of a residual septal device defect: a case report.

Authors:  Felipe Hernandez Hernandez; Jose A Linares Vicente; David Ibañez Muñoz; Jose R Ruiz Arroyo
Journal:  Eur Heart J Case Rep       Date:  2022-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.